Category C—There are no adequate and well-controlled studies in pregnant women; GDM may be a problem with all SGAs; may cause extrapyramidal and/or withdrawal symptoms in neonates with third trimester exposure
All atypicals may increase mortality in elderly patients by 1.7 times greater than placebo. No dosage adjustment is recommended; consider initiating at a low end of the dosage range, with slower titration.
No dosage adjustment necessary.
Undergoes extensive hepatic metabolism and systemic exposure may be increased; use with caution.